NightHawk Biosciences Inc (NHWK)

[dia76ca]

The last slide of the most recent presentation has a lot of very important information. Here it is...

"* mAb to TNFRSF25, drives the development of antigen-specific CD8+ T cells (this effect mimics TLIA, the natural monogamous ligand of TNFRSF25)
*mAb to TNFRSF25 results in costimulation and expansion of antigenexperienced memory T cells, both CD4+ and CD8+ – notable is a significantly enhanced effect on memory CD8+ T cells ?
*Costimulation occurs only in the context of TCR recognition of antigen ? TNFRSF25 appears to have superior activity in stimulating memory CD8+ cells relative to OX40, 4-1BB and GITR ?
*Agonism with TNFRSF25 mAb leads to increases in effector cytokine and effector immune function, and increases survival in mouse models ?
*In mouse melanoma models, TNFRSF25 mAb results in increased survival compared to agonism of OX40, GITR, 4-1BB with respective agonist mAbs"

This new Pelican drug appears to be more effective than OX40...However how will it COMBINE with OX40? In other words, How will PTX-25 combine with ComPACT? I am sure they are looking at this... it could be very significant! The preclinical work points to ComPACT being more effective than ImPACT and PTX-25 being even more effective...so a ComPACT and PTX-25 combination will be of great interest!